An experimental ovarian cancer drug, elenagen, more than doubled median survival in a 30-patient mid-stage trial in Belarus. The drug was added to gemcitabine and reduced mortality risk by nearly 60%.
Final analysis of Merck's Phase 3 KEYNOTE-B96 trial shows KEYTRUDA plus paclitaxel with or without bevacizumab significantly improved overall survival in platinum-resistant recurrent ovarian cancer patients, reducing death risk by 18%.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07567573 |
Validation of ESGO Quality Indicators in Advanced Ovarian Cancer Surgery |
COMPLETED |
